Table 1 Univariate Cox proportional hazard regression analysis for OS, DFS and PFS

From: Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment

Characteristics

No.

OS

HR (95% CI)

p

DFS

HR (95% CI)

p

PFS

HR (95% CI)

p

pH2AX (high vs. low)

21/63

2.220 (1.142–4.315)

0.019

2.457 (1.390–4.343)

0.002

2.195 (1.259–3.827)

0.006

MAP17 (high vs low)

25/65

1.470 (0.754–2.866)

0.258

1.719 (1.007–2.935)

0.047

1.692 (0.994–2.879)

0.05

Differentiation

 UD

2

1.0

0.023

1.0

0.127

1.0

0.127

 Grade 1

10

0.062 (0.04–1.028)

0.052

0.260 (0.054–1.246)

0.030

0.171 (0.035–0.840)

0.030

 Grade 2

18

0.537 (0.066–4.362)

0.561

0.566 (0.129–2.476)

0.165

0.345 (0.77–1.550)

0.165

 Grade 3

35

1.077 (0.144–8.034)

0.943

0.495 (0.117–2.103)

0.120

0.311 (0.71–1.354)

0.120

MAP17–pH2AX

Score 2 vs Score 0

12/42

3.123 (1.327–7.294)

0.009

3.072 (1.455–6.485)

0.003

2.711 (1.303–5.600)

0.008

  1. Score 2: high levels of both pH2AX and MAP17; Score 0: low levels of both pH2AX and MAP17
  2. OS overall survival, DFS disease-free survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, UD undifferentiated, MAP17–pH2AX combined score for immunohistochemical expression of pH2AX and MAP17